Cystic Fibrosis Foundation distributed the following clinical trial updates during the month of July. Click the trial title to get more details.
Two alerts were issued on July 28, 2017:
Phase 2 study of VX-659 combination drug in adults with cystic fibrosis
Status: Enrolling
Description: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-659.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 40% or greater
Number of Visits: 6
Length of Participation: 8 weeks
ClinicalTrials.gov link:https://clinicaltrials.gov/ct2/show/NCT03224351
Phase 1/2 study of VX-445 combination drug in healthy adults and then in people with cystic fibrosis
Status: Enrolling
Description: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-445.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 40 to 90%
Number of Visits: 6
Length of Participation: 12 weeks
ClinicalTrials.gov link:https://clinicaltrials.gov/ct2/show/NCT03227471
One alert were issued on July 19, 2017:
RESULT: Study of liprotamase non-porcine enzymes
Status: Enrolling
Description: This randomized, parallel-assignment study is taking place at multiple care centers across the U.S. It will look at the effectiveness of liprotamase, a non-pig-derived pancreatic enzyme replacement therapy (PERT), as compared to a pig-derived PERT.
Age: 7 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 17
Length of Participation: 30 weeks
ClinicalTrials.gov Link: https://www.clinicaltrials.gov/ct2/show/NCT03051490
Three alerts were issued on July 11, 2017:
Phase 1b study of inhaled AZD5634 in adults with CF
Status: Enrolling
Description: This study is taking place at multiple care centers across the US. It will look at the safety and tolerability of the inhaled drug AZD5634 and will use a placebo control.
Age: 18 Years to 60 Years
Mutation: No Mutation Requirement
Fev1% Predicted: 40% or greater
Number of Visits: 4
Length of Participation: 4 months
ClinicalTrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT02950805
STOP: Standardized Treatment of Pulmonary Exacerbations Pilot Study
Status: Competed with results
Description: This study evaluated current physician treatment practices and patient outcomes for the management of pulmonary exacerbations (PEx). The goal was to collect this information so that it could later inform a future study of treatments of PEx.
Age: 12 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 4
Length of Participation: 28 days
ClinicalTrials.gov Link: N/A
Status: Competed with results
Description: This study looked at the safety and effectiveness of Relizorb®, a new digestive enzyme cartridge designed for people with pancreatic insufficiency (PI) that can be used in-line with enteral tube feeding. This cartridge delivers the digestive enzyme lipase, which helps the body digest fats contained in the tube-feeding formula.
Age: 4 Years to 82 Years
Mutation: No Mutation Requirement
Fev1% Predicted: Less than 100%
Number of Visits: 4
Length of Participation: 27 days
ClinicalTrials.gov Link:https://www.clinicaltrials.gov/ct2/show/NCT02598128